Clinical usefulness of serum HBV DNA measurement with a non radioactive chemiluminescence method

International Hepatology Communications

Volumn 6, Issue 6, 1997, Pages 324-331

  Suzuki, Hiroshi ^a   Sata, Michio ^a   Sasaki, Masaru ^a   Tanaka, Eisuke ^a   Yamakawa, Yohsuke ^a   Tanikawa, Kyuichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA polymerase; HBV DNA; non radioactive measurement

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ADULT; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HEPATITIS B; HUMAN; MALE; PRIORITY JOURNAL; TECHNIQUE;

EID: 0031106064     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4346(97)00364-2     Document Type: Article

References (14)

1. [1] Chau KH, Margie MP, Decker RH, Mushahwar IK, Overby LR. Serodiagnosis of recent hepatitis B infection by IgM class anti-HBc. Hepatology 1983; 3: 142-149.
2. [2] Kaplan PM, Greenman JL, Neal AE. DNA polymerase associated with human hepatitis B antigen. J Virol 1973; 12: 995-1005.
3. [3] Kosaka Y, Takase K, Kojima M, Shimizu M, Inoue K, Yoshiba M, Tanaka S, et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991; 100: 1087-1094.
4. [4] Akahane Y, Yamanaka T, Suzuki H, Sugai Y, Tsuda F, Yotsumoto S, Omi S, et al. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990; 99: 1113-1119.
5. [5] Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-591.
6. [6] Takatori M, Ibabuchi S, Okuse C, Teramoto T, Osada T, Murayama M, Yasuda K, et al. Evaluation of serum HBV DNA levels by branched DNa probe assay in HBV carriers, especially HBe antigen negative cases. Acta Hepatol Jpn 1996; 3: 139-144.
7. [7] Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection [see comments]. N Engl J Med 1995; 333: 1657-1661.
8. [8] Mitamura K. Acta Hepatol Jpn 1982; 12: 1091-1095.
9. [9] Barlet V, Cohard M, Thelu MA, Chaix MJ, Baccard C, Zarski JP, Seigneurin JM. Quantitative detection of hepatitis B virus DNA in serum using chemiluminescence: comparison with radioactive solution hybridization assay. J Virol Methods 1994; 49: 141-151.
10. [10] Zaaijer HL, Ter BF, Cuypers HT, Hermus MC, Lelie PN. Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol 1994; 32: 2088-2091.
11. [11] De LX, Gallian P, De MP. Evaluation of a chemiluminescent molecular hybridization assay for the detection and quantitation of hepatitis B virus-DNA in serum. Microbiologica 1995; 18: 207-213.
12. [12] Wu J, Sullivan DE, Gerber MA. Quantitative polymerase chain reaction for hepatitis B virus DNA. J Virol Methods 1994; 49: 331-341.
13. [13] Hendricks DA, Stowe BJ, Hoo BS, Kolberg J, Irvine BD, Neuwald PD, Urdea MS, et al. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am J Clin Pathol 1995; 104: 537-546.
14. [14] Aspinall S, Steele AD, Peenze I, Mphahlele MJ. Detection and quantitation of hepatitis B virus DNA: comparison of two commercial hybridization assays with polymerase chain reaction. J Viral Hepat 1995; 2: 107-111.